Nature Communications (Apr 2016)
miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia
- Xi Jiang,
- Chao Hu,
- Stephen Arnovitz,
- Jason Bugno,
- Miao Yu,
- Zhixiang Zuo,
- Ping Chen,
- Hao Huang,
- Bryan Ulrich,
- Sandeep Gurbuxani,
- Hengyou Weng,
- Jennifer Strong,
- Yungui Wang,
- Yuanyuan Li,
- Justin Salat,
- Shenglai Li,
- Abdel G. Elkahloun,
- Yang Yang,
- Mary Beth Neilly,
- Richard A. Larson,
- Michelle M. Le Beau,
- Tobias Herold,
- Stefan K. Bohlander,
- Paul P. Liu,
- Jiwang Zhang,
- Zejuan Li,
- Chuan He,
- Jie Jin,
- Seungpyo Hong,
- Jianjun Chen
Affiliations
- Xi Jiang
- Department of Cancer Biology, University of Cincinnati
- Chao Hu
- Department of Cancer Biology, University of Cincinnati
- Stephen Arnovitz
- Department of Medicine, Section of Hematology/Oncology, University of Chicago
- Jason Bugno
- Department of Biopharmaceutical Sciences College of Pharmacy, The University of Illinois
- Miao Yu
- Department of Chemistry and Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago
- Zhixiang Zuo
- Department of Cancer Biology, University of Cincinnati
- Ping Chen
- Department of Medicine, Section of Hematology/Oncology, University of Chicago
- Hao Huang
- Department of Medicine, Section of Hematology/Oncology, University of Chicago
- Bryan Ulrich
- Department of Medicine, Section of Hematology/Oncology, University of Chicago
- Sandeep Gurbuxani
- Department of Pathology, University of Chicago
- Hengyou Weng
- Department of Cancer Biology, University of Cincinnati
- Jennifer Strong
- Department of Cancer Biology, University of Cincinnati
- Yungui Wang
- Department of Cancer Biology, University of Cincinnati
- Yuanyuan Li
- Department of Medicine, Section of Hematology/Oncology, University of Chicago
- Justin Salat
- Department of Medicine, Section of Hematology/Oncology, University of Chicago
- Shenglai Li
- Department of Medicine, Section of Hematology/Oncology, University of Chicago
- Abdel G. Elkahloun
- Division of Intramural Research, National Human Genome Research Institute, NIH
- Yang Yang
- Department of Biopharmaceutical Sciences College of Pharmacy, The University of Illinois
- Mary Beth Neilly
- Department of Medicine, Section of Hematology/Oncology, University of Chicago
- Richard A. Larson
- Department of Medicine, Section of Hematology/Oncology, University of Chicago
- Michelle M. Le Beau
- Department of Medicine, Section of Hematology/Oncology, University of Chicago
- Tobias Herold
- Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität
- Stefan K. Bohlander
- Department of Molecular Medicine and Pathology, University of Auckland
- Paul P. Liu
- Division of Intramural Research, National Human Genome Research Institute, NIH
- Jiwang Zhang
- Oncology Institute, Cardinal Bernardin Cancer Center, Loyola University Medical Center
- Zejuan Li
- Department of Medicine, Section of Hematology/Oncology, University of Chicago
- Chuan He
- Department of Chemistry and Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago
- Jie Jin
- Department of Hematology, The First Affiliated Hospital Zhejiang University
- Seungpyo Hong
- Department of Biopharmaceutical Sciences College of Pharmacy, The University of Illinois
- Jianjun Chen
- Department of Cancer Biology, University of Cincinnati
- DOI
- https://doi.org/10.1038/ncomms11452
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 15
Abstract
Mir-22 has been shown to be an oncogenic microRNA in breast cancer and myelodysplastic syndrome. Here, the authors show that mir-22 functions as a tumour suppressor in de novoacute myeloid leukaemia by inhibiting the expression of several oncogenes and that restoring mir-22 expression suppresses AML progression.
